| T2051 |
SKLB4771
|
1370256-78-2
|
98%
|
|
|
SKLB4771 (FLT3-IN-1) is a novel potent and selective Flt3 inhibitor.
|
| T4261 |
BPR1J-097 hydrochloride (1327167-19-0(free base))
|
T4261
|
98%
|
|
|
BPR1J-097, a new-type small molecule FLT-3 inhibitor(IC50=11±7 nM), is with great anti-tumor activities in vivo.
|
| T2272 |
BPR1J-097
|
1327167-19-0
|
98%
|
|
|
BPR1J-097) is a novel FLT-3 inhibitor(IC50: 11±7 nM) with promising in vivo anti-tumor activities. It also inhibits FLT-3 D835Y (IC50: 3 nM).
|
| T10531 |
BGB-102
|
807640-87-5
|
98%
|
|
|
BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3, which may be useful in the study of macular deg...
|
| T7673 |
ATH686
|
853299-52-2
|
|
|
|
ATH686 is an potent and selective Inhibitor of FLT3.
|
| T14072 |
A-443654
|
552325-16-3
|
|
|
|
A-443654 is a pan-Akt inhibitor. A-443654 has equal potency against Akt1, Akt2, or Akt3 within cells (Ki=160 pM).
|
| T2116 |
AEE788
|
497839-62-0
|
|
|
|
AEE788 (NVP-AEE 788) has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
|
| T6S0033 |
Crotonoside
|
1818-71-9
|
|
|
|
1. Crotonoside (Isoguanosine) has much more active than adenosine in reducing the blood pressure in rabbits and cats, in decreasing the tone of isolated intestin...
|
| TQ0235 |
AC710
|
1351522-04-7
|
|
|
|
AC710 is a potent PDGFR inhibitor (Kds: 0.6, 1, 1.57, 1.3, 1 nM for FLT3, KIT, CSF1R, PDGFRα and PDGFRβ).
|
| TQ0317 |
R1530
|
882531-87-5
|
|
|
|
R1530 is a multikinase inhibitor with antineoplastic and antiangiogenesis activities.
|
| T7104 |
Dovitinib lactate
|
692737-80-7
|
100%
|
|
|
Dovitinib lactate (TKI-258 lactate)(TKI258) lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) (IC50 :5 nM).
|
| T8317 |
5'-Fluoroindirubinoxime
|
861214-33-7
|
100%
|
|
|
5'-Fluoroindirubinoxime (5'-FIO) is a potent FLT3 inhibitor( IC50 : 15 nM).
|
| T3621 |
Brigatinib
|
1197953-54-0
|
100%
|
|
|
Brigatinib (AP-26113) is a highly potent and selective ALK inhibitor.
|
| T35570 |
Chiauranib
|
1256349-48-0
|
96.25%
|
|
|
Chiauranib is a multi-target inhibitor against tumor angiogenesis and exhibits potent anticancer effects. Chiauranib potently inhibits the angiogenesis-related k...
|
| T15335 |
FN-1501
|
1429515-59-2
|
96.35%
|
|
|
FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively). FN-1...
|
| T6458 |
CYC-116
|
693228-63-6
|
96.6%
|
|
|
CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM, is less potent to VEGFR2 (Ki of 44 nM), with 50-fold greater potency than CDKs, not active a...
|
| T13564 |
AZ7550
|
1421373-99-0
|
97.07%
|
|
|
AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).
|
| T5164 |
Cabozantinib hydrochloride
|
1817759-42-4
|
97.09%
|
|
|
Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM...
|
| T38562 |
AKN-028
|
1175017-90-9
|
97.3%
|
|
|
AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.
|
| T16750 |
Rigosertib
|
592542-59-1
|
97.33%
|
|
|
Rigosertib (ON-01910) is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer a...
|
